AstraZeneca and Daiichi Sankyo’s (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation and who require…
Cancer patients receiving anthracycline chemotherapy have more than twice the risk of developing heart failure compared to their peers without cancer. The ground-breaking RESILIENCE project aims to prevent heart failure in patients who need anthracyclines to treat their cancer. International…
FDA approves BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic NSCLC. Pfizer announced that FDA has approved BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as…